Literature DB >> 32860417

A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection.

William C Chen1, Harish N Vasudevan1, Abrar Choudhury1,2, Melike Pekmezci3, Calixto-Hope G Lucas3, Joanna Phillips3, Stephen T Magill2, Matthew S Susko1, Steve E Braunstein1, Nancy Ann Oberheim Bush2, Lauren Boreta1, Jean L Nakamura1, Javier E Villanueva-Meyer4, Penny K Sneed1, Arie Perry3, Michael W McDermott1, David A Solomon2, Philip V Theodosopoulos2, David R Raleigh1,2.   

Abstract

BACKGROUND: Prognostic markers for meningioma are needed to risk-stratify patients and guide postoperative surveillance and adjuvant therapy.
OBJECTIVE: To identify a prognostic gene signature for meningioma recurrence and mortality after resection using targeted gene-expression analysis.
METHODS: Targeted gene-expression analysis was used to interrogate a discovery cohort of 96 meningiomas and an independent validation cohort of 56 meningiomas with comprehensive clinical follow-up data from separate institutions. Bioinformatic analysis was used to identify prognostic genes and generate a gene-signature risk score between 0 and 1 for local recurrence.
RESULTS: We identified a 36-gene signature of meningioma recurrence after resection that achieved an area under the curve of 0.86 in identifying tumors at risk for adverse clinical outcomes. The gene-signature risk score compared favorably to World Health Organization (WHO) grade in stratifying cases by local freedom from recurrence (LFFR, P < .001 vs .09, log-rank test), shorter time to failure (TTF, F-test, P < .0001), and overall survival (OS, P < .0001 vs .07) and was independently associated with worse LFFR (relative risk [RR] 1.56, 95% CI 1.30-1.90) and OS (RR 1.32, 95% CI 1.07-1.64), after adjusting for clinical covariates. When tested on an independent validation cohort, the gene-signature risk score remained associated with shorter TTF (F-test, P = .002), compared favorably to WHO grade in stratifying cases by OS (P = .003 vs P = .10), and was significantly associated with worse OS (RR 1.86, 95% CI 1.19-2.88) on multivariate analysis.
CONCLUSION: The prognostic meningioma gene-expression signature and risk score presented may be useful for identifying patients at risk for recurrence.
Copyright © 2020 by the Congress of Neurological Surgeons.

Entities:  

Keywords:  Biomarker; Expression; Gene; Gene expression; Meningioma; Prognostic; Radiation; Recurrence; Resection; Survival; WHO grade

Mesh:

Year:  2020        PMID: 32860417      PMCID: PMC7735867          DOI: 10.1093/neuros/nyaa355

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   5.315


  57 in total

1.  Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression.

Authors:  H Kim; K-J Park; B-K Ryu; D-H Park; D-S Kong; K Chong; Y-S Chae; Y-G Chung; S I Park; S-H Kang
Journal:  Neuropathol Appl Neurobiol       Date:  2019-07-05       Impact factor: 8.090

2.  Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy.

Authors:  Sebastian Adeberg; Christian Hartmann; Thomas Welzel; Stefan Rieken; Daniel Habermehl; Andreas von Deimling; Jürgen Debus; Stephanie E Combs
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-02       Impact factor: 7.038

3.  Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.

Authors:  Adriana Olar; Khalida M Wani; Erik P Sulman; Alireza Mansouri; Gelareh Zadeh; Charmaine D Wilson; Franco DeMonte; Gregory N Fuller; Kenneth D Aldape
Journal:  Brain Pathol       Date:  2014-10-29       Impact factor: 6.508

Review 4.  Meningiomas in children and adolescents: a meta-analysis of individual patient data.

Authors:  Rishi S Kotecha; Elaine M Pascoe; Elisabeth J Rushing; Lucy B Rorke-Adams; Ted Zwerdling; Xing Gao; Xin Li; Stephanie Greene; Abbas Amirjamshidi; Seung-Ki Kim; Marco A Lima; Po-Cheng Hung; Fayçal Lakhdar; Nirav Mehta; Yuguang Liu; B Indira Devi; B Jayanand Sudhir; Morten Lund-Johansen; Flemming Gjerris; Catherine H Cole; Nicholas G Gottardo
Journal:  Lancet Oncol       Date:  2011-11-15       Impact factor: 41.316

5.  Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.

Authors:  Petra Obexer; Judith Hagenbuchner; Thomas Unterkircher; Nora Sachsenmaier; Christoph Seifarth; Günther Böck; Verena Porto; Kathrin Geiger; Michael Ausserlechner
Journal:  Mol Biol Cell       Date:  2009-02-11       Impact factor: 4.138

6.  Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment.

Authors:  Salah Hammouche; Simon Clark; Alex Hie Lin Wong; Paul Eldridge; Jibril Osman Farah
Journal:  Acta Neurochir (Wien)       Date:  2014-06-26       Impact factor: 2.216

7.  Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.

Authors:  Victoria E Clark; E Zeynep Erson-Omay; Akdes Serin; Jun Yin; Justin Cotney; Koray Ozduman; Timuçin Avşar; Jie Li; Phillip B Murray; Octavian Henegariu; Saliha Yilmaz; Jennifer Moliterno Günel; Geneive Carrión-Grant; Baran Yilmaz; Conor Grady; Bahattin Tanrikulu; Mehmet Bakircioğlu; Hande Kaymakçalan; Ahmet Okay Caglayan; Leman Sencar; Emre Ceyhun; A Fatih Atik; Yaşar Bayri; Hanwen Bai; Luis E Kolb; Ryan M Hebert; S Bulent Omay; Ketu Mishra-Gorur; Murim Choi; John D Overton; Eric C Holland; Shrikant Mane; Matthew W State; Kaya Bilgüvar; Joachim M Baehring; Philip H Gutin; Joseph M Piepmeier; Alexander Vortmeyer; Cameron W Brennan; M Necmettin Pamir; Türker Kiliç; Richard P Lifton; James P Noonan; Katsuhito Yasuno; Murat Günel
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

8.  Genomic landscape of intracranial meningiomas.

Authors:  Wenya Linda Bi; Malak Abedalthagafi; Peleg Horowitz; Pankaj K Agarwalla; Yu Mei; Ayal A Aizer; Ryan Brewster; Gavin P Dunn; Ossama Al-Mefty; Brian M Alexander; Sandro Santagata; Rameen Beroukhim; Ian F Dunn
Journal:  J Neurosurg       Date:  2016-01-15       Impact factor: 5.115

9.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

10.  GNE: a deep learning framework for gene network inference by aggregating biological information.

Authors:  Kishan Kc; Rui Li; Feng Cui; Qi Yu; Anne R Haake
Journal:  BMC Syst Biol       Date:  2019-04-05
View more
  2 in total

1.  Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.

Authors:  Stephen T Magill; Charlotte D Eaton; Abrar Choudhury; Briana C Prager; William C Chen; Martha A Cady; Kyounghee Seo; Calixto-Hope G Lucas; Tim J Casey-Clyde; Harish N Vasudevan; S John Liu; Javier E Villanueva-Meyer; Tai-Chung Lam; Jenny Kan-Suen Pu; Lai-Fung Li; Gilberto Ka-Kit Leung; Danielle L Swaney; Michael Y Zhang; Jason W Chan; Zhixin Qiu; Michael V Martin; Matthew S Susko; Steve E Braunstein; Nancy Ann Oberheim Bush; Jessica D Schulte; Nicholas Butowski; Penny K Sneed; Mitchel S Berger; Nevan J Krogan; Arie Perry; Joanna J Phillips; David A Solomon; Joseph F Costello; Michael W McDermott; Jeremy N Rich; David R Raleigh
Journal:  Nat Genet       Date:  2022-05-09       Impact factor: 41.307

Review 2.  Synthesizing Molecular and Immune Characteristics to Move Beyond WHO Grade in Meningiomas: A Focused Review.

Authors:  Nivedha V Kannapadi; Pavan P Shah; Dimitrios Mathios; Christopher M Jackson
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.